Scholarlink

<p>Radioligand therapy (RLT) using [<sup>177</sup>Lu]Lu-PSMA-617 represents an innovative approach for treating metastatic castration-resistant prostate cancer (mCRPC). This therapy employs radioactively labeled ligands that specifically bind to prostate-specific membrane antigen (PSMA), allowing targeted radiation directly to tumor cells. Following its approval by the European Medicines Agency (EMA), the VISION trial demonstrated significant improvements in survival rates and quality of life for patients compared to traditional therapies. Numerous clinical studies are currently underway to evaluate the effectiveness of [<sup>177</sup>Lu]Lu-PSMA-617 in combination with other treatments and across various disease stages. Despite these advancements, there remains a&#xa0;critical need for further research on optimal dosing, application and patient selection to enhance therapeutic outcomes and explore new treatment avenues.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PSMA-Radioligandentherapie – State of the Art

  • 期刊论文

  • 发表日期：

    2025年8月27日

查看全文
  • Christoph Berliner,
  • Viktor Grünwald,
  • Ulrich Krafft,
  • Stephan Himmen,
  • Wolfgang P. Fendler

摘要

Radioligand therapy (RLT) using [177Lu]Lu-PSMA-617 represents an innovative approach for treating metastatic castration-resistant prostate cancer (mCRPC). This therapy employs radioactively labeled ligands that specifically bind to prostate-specific membrane antigen (PSMA), allowing targeted radiation directly to tumor cells. Following its approval by the European Medicines Agency (EMA), the VISION trial demonstrated significant improvements in survival rates and quality of life for patients compared to traditional therapies. Numerous clinical studies are currently underway to evaluate the effectiveness of [177Lu]Lu-PSMA-617 in combination with other treatments and across various disease stages. Despite these advancements, there remains a critical need for further research on optimal dosing, application and patient selection to enhance therapeutic outcomes and explore new treatment avenues.